These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 29974604)

  • 41. [Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].
    Li Q; Xu T; Wang XF
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):904-7. PubMed ID: 20193328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.
    Abufaraj M; Shariat SF; Foerster B; Pozo C; Moschini M; D'Andrea D; Mathieu R; Susani M; Czech AK; Karakiewicz PI; Seebacher V
    World J Urol; 2018 Feb; 36(2):231-240. PubMed ID: 29127452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.
    Nielsen ME; Bastian PJ; Palapattu GS; Trock BJ; Schoenberg MP; Chan T; Rogers CG
    Urology; 2007 Dec; 70(6):1091-5. PubMed ID: 18158024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial.
    Xu C; Jiang S; Zou L; Sheng L; Shi G; Xu B; Wang Z; Xu D; Xie X; Luo J; Guo J; Jiang H
    Cancer; 2023 Feb; 129(3):415-425. PubMed ID: 36477612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how?
    Ritch CR; Clark PE; Morgan TM
    Urol Clin North Am; 2013 May; 40(2):295-304. PubMed ID: 23540786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
    Kuroda K; Ishii N; Fukasawa K; Shirai M; Tajima M; Matsushima M; Miura K; Takanami M; Matsuhashi M; Kuwabara T; Matsumoto H; Sugita M
    Hinyokika Kiyo; 1998 Aug; 44(8):547-52. PubMed ID: 9783189
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Invasive bladder cancer: a single-institution experience with bladder-sparing approach.
    Zapatero A; Martín de Vidales C; Marín A; Cerezo L; Arellano R; Rabadán M; Pérez-Torrubia A
    Int J Cancer; 2000 Oct; 90(5):287-94. PubMed ID: 11091353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Radiochemotherapy for invasive bladder cancer : An update].
    Tselis N; Prott FJ; Ott O; Weiss C; Rödel C
    Urologe A; 2018 Jun; 57(6):679-685. PubMed ID: 29651707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
    Kamiya N; Suzuki H; Suyama T; Kobayashi M; Fukasawa S; Sekita N; Mikami K; Nihei N; Naya Y; Ichikawa T
    Int J Clin Oncol; 2017 Apr; 22(2):353-358. PubMed ID: 27744487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer.
    Bono AV; Benvenuti C; Damiano G; Lovisolo J
    Urology; 1994 Sep; 44(3):329-34; discussion 334-5. PubMed ID: 8073548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
    Xu S; Tan S; Wu T; Gu J; Xu L; Che X
    Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy.
    Ge P; Wang ZC; Yu X; Lin J; He Q
    BMC Urol; 2015 May; 15():46. PubMed ID: 26025446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
    Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
    Blute ML; Rushmer TJ; Shi F; Fuller BJ; Abel EJ; Jarrard DF; Downs TM
    J Urol; 2015 Nov; 194(5):1214-9. PubMed ID: 26173101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
    Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
    Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.